| Name | Title | Contact Details |
|---|
TruVision is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Over the years we have always placed the needs of those we serve as our highest priority. We have earned a reputation for providing excellent state-of-the art medical care in a family-centered, healing environment.
Lane Individual Practice Association is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ReVision Optics®, Inc., (RVO) is a privately held corporation headquartered in Southern California, USA. RVO`s main focus is developing unique optical solutions for the treatment of presbyopia. Fueled by a belief that no one should ever have to hold a menu out at arm`s length, the company developed the Raindrop® Near Vision Corneal Inlay, a unique patented refractive surgery solution. This inlay is designed to improve the near vision that has been lost by the eye`s natural aging process, called presbyopia. The Company is actively pursuing regulatory approvals and market opportunities for Raindrop® worldwide, and is committed to ridding the world of reading glasses, one satisfied patient at a time.
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.